Skip to main content

Table 4 Prevalence of primary and secondary study end-points for FVL G1691A, PT G20210A, and ACE-ins/del Genotypes.

From: Thrombotic gene polymorphisms and postoperative outcome after coronary artery bypass graft surgery

   FVL 1691 G/G
(n = 196)
FVL 1691 G/A
(n = 24)
p value PT 20210
G/G
(n = 212)
PT 20210
G/A
(n = 8)
p value ACE I/I
(n = 30)
ACE I/D
(n = 94)
ACE D/D
(n = 57)
p value
Re-exploration due to bleeding, n (%) No 193 (98.5) 23 (95.8) NS 209 (98.6) 7 (87.5) NS 29 (96.7) 93 (98.9) 55 (96.5) NS
  Yes 3 (1.5) 1 (4.2)   3 (1.4) 1 (12.5)   1 (3.3) 1 (1.1) 2 (3.5)  
Perioperative acute MI, n (%) No 194 (99.0) 24 (100) NS 211 (99.5) 7 (87.5) 0.072 29 (96.7) 93 (98.9) 55 (96.5) NS
  Yes 2 (1.0) 0   1 (0.5) 1 (12.5)   1 (3.3) 1 (1.1) 2 (3.5)  
Postoperative stroke, n (%) No 194 (99.0) 24 (100) NS 210 (99.0) 8 (100) NS 30 (100) 93 (98.9) 57 (100) NS
  Yes 2 (1.0) 0   2 (0.9) 0   0 1 (1.1) 0  
Respiratory insufficiency, n (%) No 191 (97.5) 24 (100) NS 207 (97.6) 8 (100) NS 30 (100) 92 (97.9) 55 (96.5) NS
  Yes 5 (2.6) 0   5 (2.4) 0   0 2 (2.1) 2 (3.5)  
Renal insufficiency, n (%) No 191 (97.5) 24 (100) NS 206 (97.2) 8 (100) NS 30 (100) 92 (97.9) 55 (96.5) NS
  Yes 5 (2.6) 0   5 (2.4) 0   0 2 (2.1) 2 (3.5)  
Event-free survival, n (%) No 9 (4.6) 1 (4.2) NS 9 (4.2) 1 (12.5) NS 1 (3.3) 4 (4.3) 4 (7.0) NS
  Yes 187 (95.4) 23 (95.8)   203 (95.8) 7 (87.5)   29 (96.7) 90 (95.7) 53 (93.0)  
Overall death at 5-years, n (%) No 189 (96.4) 23 (95.8) NS 205 (96.7) 7 (87.5) NS 30 (100) 91 (96.8) 54 (94.7) NS
  Yes 7 (3.6) 1 (4.2)   7 (3.3) 1 (12.5)   0 3 (3.2) 3 (5.3)  
  1. FVL indicates factor V Leiden; PT 20210, prothrombin/factor II; ACE-ins/del, angiotensin-converting enzyme gene insertion/deletion polymorphism; MI, myocardial infarction; NS, non-significant